Established on February 17th 2023, RetinaReadRisk (RRR) is a pioneering company in the field of early detection and diagnosis of Diabetic Retinopathy (DR), which is the principal cause of vision loss and blindness. We must know Diabetic Retinopathy (DR) is a microvascular complication of type 1 and type 2 diabetes that affects the small vessels of the retina.
The Company is part of a multidisciplinary consortium composed of seven prominent partners, including the Pere Virgili Healthcare Institute (IISPV), the Health Catalan Institute (ICS), GENESIS Biomed, Telefónica SA, Grupo TRC, and the French organizations Foundation de l’Avenir and E’Seniors. This alliance allows them to leverage a wide range of expertise and resources to drive their mission of transforming diabetic retinopathy management and improving visual health in rural communities.
We have two algorithms designed for the detection and control of diabetic retinopathy. One is an image reading system of the retina that determines whether there is diabetic retinopathy and its severity, whether it’s mild, moderate, or severe. The second algorithm determines, based on clinical data of the patient, the risk of developing diabetic retinopathy for each patient. If the risk is low, it indicates when the next review should be scheduled, between 12 and 36 months. If there is mild diabetic retinopathy, it predicts its progression to more advanced stages based on the patient’s clinical data and indicates when the next review should be scheduled, between 3 and 12 months. Both algorithms are integrated into patient’s medical record.
The objective is to apply these two algorithms to portable retina image capture systems, called portable retinographies, which allow closed monitoring of diabetic patients from their homes.
Additionally, we aim to merge both algorithms into one, which would facilitate its integration into retinographies and the patient’s medical record.
RetinaReadRisk is a spin-off from Pere Virgili Health Research Institute (IISPV).
GENESIS Biomed has played a pivotal role in nurturing the growth of the spin-off, offering support from its inception within the European project framework to a substantial financial commitment through the GENESIS Tech Transfer Boost. With GENESIS’ CEO, Josep Lluís Falcó stepping in as interim CEO, their involvement extended to guiding the spin-off through crucial developmental stages, including the selection process for the current CEO. GENESIS Biomed is currently looking for a full-time CEO for RRR, as part of their activities as venture builder, as long as preparing RRR for its next financial round with investors.
Moreover, RRR is focus on and dedicated to continuous technological innovation to consistently deliver top-notch services to our clientele. Using the knowledge of our experimental Team and AI and 5G technologies allows the detection of the disease early and the design and effective treatment to improve the lifestyle’s population.
Spin-off company from Pere Virgili Health Institute. Support received from EIT Health and European Union and Instituto de Salud Carlos III – Ministerio de Ciencia, Innovacion y Universidades
01 d'September de 2021
